WB
H M R Mk
Endogenous
300
Rabbit IgG
#Q7Z333
23064
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human senataxin protein.
Background
Senataxin is a ubiquitously expressed RNA-DNA helicase encoded by the SETX gene. Senataxin is well known for resolving RNA-DNA hybrid structures known as R-loops, which can form during gene transcription when the template DNA strand hybridizes with nascent mRNA (1). Senataxin is also recruited to DNA double-strand breaks (DSBs) on active genes, where it promotes cell survival and prevents translocations (2). Although R-loops may positively regulate gene expression under certain conditions, unresolved R-loops can promote DNA damage and have been linked to neurodegenerative disorders (3). Indeed, senataxin mutations are the root cause of the neurological conditions ataxia with oculomotor apraxia type 2 (AOA2) and juvenile amyotrophic lateral sclerosis (ALS4) (4-7). Senataxin dysregulation has also been observed in several types of cancer, where it may play a tumor suppressive role (8). Interestingly, loss of senataxin has been found to cause accumulation of RNA-DNA hybrids in the cytoplasm, consequently promoting an innate immune response via cGAS and IRF3 (9). This innate immune activation could provide an additional link between senataxin dysfunction and disease (9).
- Hasanova, Z. et al. (2023) Nucleic Acids Res 51, 2818-2837.
- Cohen, S. et al. (2018) Nat Commun 9, 533.
- Groh, M. and Gromak, N. (2014) PLoS Genet 10, e1004630.
- Moreira, M.C. et al. (2004) Nat Genet 36, 225-7.
- Le Ber, I. et al. (2004) Brain 127, 759-67.
- Avemaria, F. et al. (2011) Amyotroph Lateral Scler 12, 228-30.
- Kannan, A. et al. (2022) Brain 145, 3072-3094.
- Gatti, V. et al. (2023) Cell Death Discov 9, 145.
- Crossley, M.P. et al. (2023) Nature 613, 187-194.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.